Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

38 results about "Analogues/Derivatives" patented technology

Treating renal disease, burns, wounds and spinal cord injury with selective androgen receptor modulators

This invention provides: 1) a method of treating a subject suffering from, or predisposed to a kidney disease or disorder; 2) a method of treating a subject suffering from a wound, or reducing the incidence of, or mitigating the severity of a wound in a subject; 3) a method of treating a subject suffering from a burn, or reducing the incidence of, or mitigating the severity of a burn in a subject, comprising the step of administering to said subject a selective androgen receptor modulator (SARM) compound; 4) a method of treating a subject suffering from a spinal cord injury, by administering to the subject a selective androgen receptor modulator (SARM) and / or an analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, prodrug, polymorph, impurity or crystal of said SARM compound, or any combination thereof.
Owner:UNIV OF TENNESSEE RES FOUND

Compositions and methods for viscosupplementation

The invention provides viscosupplementation compositions that include hyaluronic acid, or a polymer thereof and a tribonectin, or an analog, derivative, or fragment thereof. Such compositions are useful for the lubrication and chondroprotection of mammalian joints.
Owner:LUBRIS

Carotenoids, carotenoid analogs, or carotenoid derivatives for the treatment of proliferative disorders

InactiveUS20060276372A1Limit hepatic fibrosisLimit progression to cirrhosisBiocideHydrocarbon active ingredientsApoptosisBiology
A method and system used for treating proliferative disorders using carotenoids, carotenoid analogs, and / or carotenoid derivatives. The method and system may be used for chemoprevention and / or chemotherapy. The method and system may induce apoptosis in target cells, tissues, and / or organs. The analog, derivative, or intermediate may be administered to a cell, a group of cells, a tissue, an organ or a subject, such that at least a portion of the undesirable consequences of the proliferative disorder are thereby reduced.
Owner:CARDAX PHARMA

Recombinant interferon alpha2 (ifnalpha2) mutants and methods of use thereof

The present invention provides IFNα2 mutants and active fragments, analogs, derivatives, and variants thereof, nucleotide molecules encoding same, pharmaceutical compositions containing the same, and methods utilizing the same for treating cancer, infectious diseases, and autoimmune diseases.
Owner:YEDA RES & DEV CO LTD

Prevention and treatment of androgen-deprivation induced osteoporosis

InactiveUS20060269611A1Suppressing inhibiting reducing riskAvoid lostPowder deliveryOrganic active ingredientsToremifeneMetabolite
This invention provides a method of treating androgen-deprivation induced osteoporosis, bone fractures or loss of bone mineral density (BMD) in a male human subject suffering from prostate cancer by administering a pharmaceutical composition comprising Toremifene and / or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof, to the subject.
Owner:GTX INCORPORATED

Prevention and treatment of androgen-deprivation induced osteoporosis

InactiveUS20070197664A1Shorten the progressDiminishing pathogenesis of a skeletal-related event (SRE)Organic active ingredientsBiocideMetaboliteSelective estrogen receptor modulator
This invention provides a method of treatment, prevention, suppression, inhibition, or reduction of risk of developing androgen-deprivation induced skeletal-related events (SRE), such as pathologic fractures, surgery to bone, radiation to bone, spinal cord compression, change in antineoplastic therapy, including changes in hormonal therapy, new bone metastases, bone loss, or a combination thereof in men suffering from prostate cancer, comprising administering to a male subject suffering from prostate cancer a selective estrogen receptor modulator (SERM) and / or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof.
Owner:GTX INCORPORATED

Method for chemoprevention of prostate cancer

InactiveUS20060270641A1Safe and effectivePreventing prostate carcinogenesisBiocideAnimal repellantsRaloxifeneMetabolite
This invention relates to the chemoprevention of prostate cancer and, more particularly, to a method of suppressing or inhibiting latent prostate cancer comprising administering to a mammalian subject a chemopreventive agent, for example raloxifene, or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, ester, or N-oxide, or mixtures thereof. The chemopreventive agent prevents, prevents recurrence of, suppresses or inhibits prostate carcinogenesis and treats prostate cancer.
Owner:UNIV OF TENNESSEE RES FOUND

Pharmaceutical dosage form

InactiveUS20120189695A1Useful in treatmentBiocideNervous disorderD-threo-methylphenidateEnantiomer
This invention relates to a oral pharmaceutical formulation for methylphenidate or its analogs, derivatives, isomers or enantiomers, including d-threo-methylphenidate.
Owner:KREMERS URBAN PHARMA

Controlled release caffeine dosage forms

Formulations capable of extended or sustained release of high levels of caffeine or analogs, derivatives and metabolites thereof have been developed The formulations contain at least two components capable of releasing the caffeine or related compound differing rates to maintain a desired plasma level.
Owner:KVK TECH

Water-dispersible carotenoids, including analogs and derivatives

A method used for synthesizing intermediates for use in the synthesis of carotenoid synthetic intermediates, carotenoid analogs, and / or carotenoid derivatives. The analog, derivative, or intermediate may be administered such that a subject's risk of experiencing diseases associated with reactive oxygen species, reactive nitrogen species, radicals and / or non-radicals may be thereby reduced. The analog or analog combination may be administered to a subject for the inhibition and / or amelioration of any disease that involves production of reactive oxygen species, reactive nitrogen species, radicals and / or non-radicals. In some embodiments, the invention may include methods for synthesizing chemical compounds including an analog or derivative of a carotenoid. The carotenoid analog or derivative may be synthetic. In some embodiments, a carotenoid analog or derivative may include at least one substituent. The substituent may enhance the solubility of the carotenoid analog or derivative such that the carotenoid analog or derivative at least partially dissolves in water.
Owner:LOCKWOOD SAMUEL F +1

Combination therapy and uses thereof for treatment and prevention of parasitic infection and disease

The invention relates to compounds, methods, uses, compositions, combinations, kits and packages for the prevention and / or treatment of parasite infection (e.g., Plasmodium parasites) and / or disease (e.g., malaria) based on uses of (a) cystamine, cysteamine, and analogs, derivatives, prodrugs, precursors thereof; an agent capable of inducing their production; and / or salts thereof, and (b) artemisinin and functional derivative, analog, conjugate, metabolite, prodrug or precursor thereof, and / or salts thereof.
Owner:MCGILL UNIV

Treatment of androgen-deprivation induced osteoporosis

The present invention provides methods for reducing the incidence of, inhibiting, suppressing, reducing the incidence of, and treating androgen-deprivation induced osteoporosis, bone fractures and / or loss of bone mineral density (BMD) in men having prostate cancer, comprising administering to a male human subject having prostate cancer a toremifene and / or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof. The present invention also provides methods of treating, preventing, suppressing, inhibiting, or reducing the incidence of hot flashes, gynecomastia, and / or hair loss in male humans having prostate cancer, comprising same.
Owner:GTX INCORPORATED

Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol

PendingUS20160074337A1Increased therapeutic benefitImproved dose determination and schedulePowder deliveryOrganic active ingredientsChemical compoundSide effect
The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to substituted hexitols such as dibromodulcitol or analogs, derivatives, or prodrugs thereof.
Owner:BROWN DENNIS

Carotenoids, carotenoid analogs, or carotenoid derivatives for the treatment of visual disabilities

InactiveUS20060270589A1Inhibit and ameliorate occurrenceStable visionBiocideSenses disorderSolubilityVitamin C
A method and system used for treating visual disabilities using carotenoids, carotenoid analogs, and / or carotenoid derivatives. The analog, derivative, or intermediate may be administered such that a subject's risk of experiencing diseases associated with visual disabilities may be thereby reduced. Analogs or derivatives of carotenoids may include substituents including for example co-antioxidants (e.g., Vitamin C and Vitamin C analogs). The carotenoid analog or derivative may be synthetic. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include an acyclic alkene including at least one substituent and / or a cyclic ring including at least one substituent. In some embodiments, a carotenoid analog or derivative may include at least one substituent. The substituent may enhance the solubility of the carotenoid analog or derivative such that the carotenoid analog or derivative at least partially dissolves in water.
Owner:CARDAX PHARMA

Extracellular NAD+ and cADPR as potent anti-inflammatory agents

A method of prophylaxis or treatment of inflammatory conditions, including, but not limited to, intestinal epithelial inflammation due to intestine-specific conditions (e.g., Crohn's disease or ulcerative colitis) or systemic causes of inflammation (e.g., endotoxemia, sepsis, hemorrhagic shock / resuscitation or pancreatitis) is disclosed. In the method of the invention, an affected patient is administered a therapeutically effective amount of a composition including an NAD-related compound, in a form that is accessible to a receptor molecule, conveyed in a pharmaceutically acceptable carrier vehicle. NAD-related compounds include nicotinamide adenine dinucleotide (NAD+), cyclic adenosine diphosphate ribose (cADPR), or functionally equivalent analogues, derivatives, metabolites or agonists thereof or prodrugs therefor. Also disclosed are ex vivo and in vivo assay methods to test candidate compounds for activity, kits for carrying out the therapeutic methods or the assay methods of the invention and articles of manufacture that include compositions for use in the methods of the invention and instructions for the use thereof.
Owner:UNIVERSITY OF PITTSBURGH

Extracellular NAD+ and cADPR as potent anti-inflammatory agents

A method of prophylaxis or treatment of inflammatory conditions, including, but not limited to, intestinal epithelial inflammation due to intestine-specific conditions (e.g., Crohn's disease or ulcerative colitis) or systemic causes of inflammation (e.g., endotoxemia, sepsis, hemorrhagic shock / resuscitation or pancreatitis) is disclosed. In the method of the invention, an affected patient is administered a therapeutically effective amount of a composition including an NAD-related compound, in a form that is accessible to a receptor molecule, conveyed in a pharmaceutically acceptable carrier vehicle. NAD-related compounds include nicotinamide adenine dinucleotide (NAD+), cyclic adenosine diphosphate ribose (cADPR), or functionally equivalent analogues, derivatives, metabolites or agonists thereof or prodrugs therefor.Also disclosed are ex vivo and in vivo assay methods to test candidate compounds for activity, kits for carrying out the therapeutic methods or the assay methods of the invention and articles of manufacture that include compositions for use in the methods of the invention and instructions for the use thereof.
Owner:UNIVERSITY OF PITTSBURGH

Carbamoyl cyclohexane derivatives for treating autism spectrum disorder

The present invention relates to trans-N-[4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-N',N'-dimethylurea (cariprazine), its salts, close analogs, derivatives, pharmaceutical compositions, metabolites and combinations for use in the treatment of symptoms of autism spectrum disorder in general, and preferably the object of the present invention is to treat one or more symptoms of autism. Furthermore, it was also found that cariprazine, its salts, close analogs, derivatives, pharmaceutical compositions, metabolites and combinations are suitable for treatment of conditions such as Asperger's syndrome, atypical autism (otherwise known as pervasive developmental disorder not otherwise specified; PDD-NOS), Rett syndrome, childhood disintegrative disorder, attention deficit hyperactivity disorder (ADHD) and sensory integration dysfunction.
Owner:RICHTER GEDEON NYRT

Application of berberine dimer analog derivatives in the preparation of drugs for preventing and treating Parkinson's disease

The invention discloses the application of berberine dimer analog derivatives in the preparation of medicines for preventing and treating Parkinson's disease. The structural formula of the berberine dimer analog derivative is shown in formula I. In the present invention, it is found that berberine dimer analogue derivatives or pharmaceutically acceptable salts thereof show better pharmacodynamic activity than the parent compound berberine on the in vitro cell model of Parkinson's disease, and it can obviously Improve the behavior of Parkinson's disease model mice, increase the number of dopaminergic neurons in the substantia nigra compacta, and increase the levels of dopamine and 3,4-dihydroxyphenylacetic acid in the striatum. Therefore, berberine dimer analog derivatives or pharmaceutically acceptable salts thereof can be made into related medicines for preventing and treating Parkinson's disease.
Owner:JINAN UNIVERSITY

Fusion protein for treating diabetes and/or obesity

PendingCN114106194ASolving bottlenecks with short half-livesExtended half-lifePeptide/protein ingredientsMetabolism disorderDiabetes mellitusObesity
The invention relates to a fusion protein for treating diabetes and / or obesity. The structure of the fusion protein is GLP-1 or an analogue and a derivative thereof-connecting peptide-albumin binding protein, the albumin binding protein comprises an ABD structural domain (GA3, ABD035, ABDon) or a DARPin capable of targeting HSA (human serum albumin). The bottleneck problem that the half-life period of GLP-1 or Ex is short is solved by connecting the GLP-1 or Ex with an ABD structural domain or DARPin protein, so that the GLP-1 or Ex can be better applied clinically. According to the present invention, the test results show that the albumin binding protein significantly prolongs the half-life period of GLP-1 or Ex, and improves the hypoglycemic activity in mice. The modified GLP-1 or Ex has a certain body weight reducing effect and can be used for treating or assisting in treating obesity.
Owner:TIANJIN INST OF IND BIOTECH CHINESE ACADEMY OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products